Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 17

1.

Predictive value in retinal vein occlusions of early versus late or incomplete ranibizumab response defined by optical coherence tomography.

Bhisitkul RB, Campochiaro PA, Shapiro H, Rubio RG.

Ophthalmology. 2013 May;120(5):1057-63. doi: 10.1016/j.ophtha.2012.11.011. Epub 2013 Feb 14.

PMID:
23415775
2.

Efficacy and safety of widely used treatments for macular oedema secondary to retinal vein occlusion: a systematic review.

Glanville J, Patterson J, McCool R, Ferreira A, Gairy K, Pearce I.

BMC Ophthalmol. 2014 Jan 21;14:7. doi: 10.1186/1471-2415-14-7. Review.

3.

[BRAVO and CRUISE: ranibizumab for the treatment of macular edema secondary to retinal vein occlusion].

Figueroa MS, Ruiz Moreno JM.

Arch Soc Esp Oftalmol. 2012 Dec;87 Suppl 1:46-53. Review. Spanish.

PMID:
24278989
4.

Ranibizumab: in macular oedema following retinal vein occlusion.

Garnock-Jones KP.

Drugs. 2011 Mar 5;71(4):455-63. doi: 10.2165/11206900-000000000-00000. Review.

PMID:
21395358
5.

[From scientific evidence to clinical practice: treatment regimens for macular edema secondary to retinal vein occlusion].

Abraldes MJ, Zapata MA, Gómez-Ulla F, García-Arumí J.

Arch Soc Esp Oftalmol. 2012 Dec;87 Suppl 1:54-62. Review. Spanish.

PMID:
24278990
6.
7.

Treatments for macular oedema following central retinal vein occlusion: systematic review.

Ford JA, Clar C, Lois N, Barton S, Thomas S, Court R, Shyangdan D, Waugh N.

BMJ Open. 2014 Feb 10;4(2):e004120. doi: 10.1136/bmjopen-2013-004120. Review.

8.

Aflibercept: newly approved for the treatment of macular edema following central retinal vein occlusion.

Evoy KE, Abel SR.

Ann Pharmacother. 2013 Jun;47(6):819-27. doi: 10.1345/aph.1R705. Epub 2013 May 14. Review.

PMID:
23673531
9.

[Management of macular edema secondary to retinal vein occlusion].

Girmens JF, Glacet-Bernard A, Kodjikian L, Nghiêm-Buffet S, Massé H, Fourmaux E, Wolff B, Roquet W, Gaucher D, Baillif S, Tadayoni R.

J Fr Ophtalmol. 2015 Mar;38(3):253-63. doi: 10.1016/j.jfo.2014.10.003. Epub 2015 Feb 13. Review. French.

10.

Central retinal vein occlusion: modifying current treatment protocols.

Ashraf M, Souka AA, Singh RP.

Eye (Lond). 2016 Apr;30(4):505-14. doi: 10.1038/eye.2016.10. Epub 2016 Feb 12. Review.

11.

Ranibizumab: the first vascular endothelial growth factor inhibitor approved for the treatment of diabetic macular edema.

Evoy KE, Abel SR.

Ann Pharmacother. 2013 Jun;47(6):811-8. doi: 10.1345/aph.1S013. Epub 2013 May 8. Review.

PMID:
23656749
12.

Intravitreal steroids versus observation for macular edema secondary to central retinal vein occlusion.

Gewaily D, Greenberg PB.

Cochrane Database Syst Rev. 2009 Jan 21;(1):CD007324. doi: 10.1002/14651858.CD007324.pub2. Review. Update in: Cochrane Database Syst Rev. 2015;9:CD007324.

13.

Central Retinal Vein Occlusion: A Review of Current Evidence-based Treatment Options.

Patel A, Nguyen C, Lu S.

Middle East Afr J Ophthalmol. 2016 Jan-Mar;23(1):44-8. doi: 10.4103/0974-9233.173132. Review.

14.

Low molecular weight heparin for the treatment of retinal vein occlusion: a systematic review and meta-analysis of randomized trials.

Lazo-Langner A, Hawel J, Ageno W, Kovacs MJ.

Haematologica. 2010 Sep;95(9):1587-93. doi: 10.3324/haematol.2010.023614. Epub 2010 Mar 19. Review.

15.

Aflibercept (Eylea, New Therapeutic Indication) -- Benefit Assessment According to §35a Social Code Book V [Internet].

Institute for Quality and Efficiency in Health Care.

Cologne, Germany: Institute for Quality and Efficiency in Health Care (IQWiG); 2013 Dec 19.

16.

Aflibercept (New Therapeutic Indication) -- Benefit Assessment According to §35a Social Code Book V [Internet].

Institute for Quality and Efficiency in Health Care.

Cologne, Germany: Institute for Quality and Efficiency in Health Care (IQWiG); 2015 Jun 11.

17.

Steroids in Central Retinal Vein Occlusion: Is There a Role in Current Treatment Practice?

Ashraf M, Souka AA.

J Ophthalmol. 2015;2015:594615. doi: 10.1155/2015/594615. Epub 2015 Oct 8. Review.

Supplemental Content

Support Center